Empirical Financial Services LLC d.b.a. Empirical Wealth Management Decreases Stock Holdings in Danaher Corporation $DHR

Empirical Financial Services LLC d.b.a. Empirical Wealth Management trimmed its position in shares of Danaher Corporation (NYSE:DHR) by 1.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,354 shares of the conglomerate’s stock after selling 338 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management’s holdings in Danaher were worth $4,021,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Hills Bank & Trust Co raised its stake in shares of Danaher by 0.3% during the first quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate’s stock valued at $3,693,000 after acquiring an additional 53 shares during the last quarter. Worth Financial Advisory Group LLC raised its stake in shares of Danaher by 4.6% during the second quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock valued at $236,000 after acquiring an additional 53 shares during the last quarter. Sageworth Trust Co raised its stake in shares of Danaher by 2.3% during the first quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate’s stock valued at $493,000 after acquiring an additional 54 shares during the last quarter. 1834 Investment Advisors Co. raised its stake in shares of Danaher by 3.3% during the first quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate’s stock valued at $342,000 after acquiring an additional 54 shares during the last quarter. Finally, Bruce G. Allen Investments LLC increased its position in shares of Danaher by 13.1% during the second quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate’s stock valued at $92,000 after buying an additional 54 shares during the period. 79.05% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

DHR has been the topic of several research analyst reports. Guggenheim reiterated a “buy” rating and set a $250.00 price target on shares of Danaher in a research report on Wednesday, July 23rd. Wall Street Zen upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research report on Friday, June 27th. Barclays reiterated an “overweight” rating and set a $225.00 price target (up previously from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Robert W. Baird upped their price objective on shares of Danaher from $225.00 to $226.00 and gave the stock an “outperform” rating in a report on Friday, July 18th. Finally, Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a report on Tuesday, September 2nd. Seventeen analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $245.91.

Danaher Stock Up 2.2%

Shares of DHR stock opened at $215.05 on Friday. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $279.41. The stock has a market cap of $153.98 billion, a P/E ratio of 45.75, a P/E/G ratio of 3.00 and a beta of 0.77. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The company has a 50 day simple moving average of $200.19 and a two-hundred day simple moving average of $197.42.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating analysts’ consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business had revenue of $5.94 billion during the quarter, compared to analysts’ expectations of $5.83 billion. During the same period in the prior year, the company earned $1.72 earnings per share. The firm’s revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher’s dividend payout ratio (DPR) is presently 27.23%.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.10% of the stock is owned by insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.